Tesamorelin
Also known as: Egrifta, Egrifta SV, Egrifta WR, Tesamorelin acetate, TH9507
Classification
Peptide
Regulatory Status
FDA-approved prescription product
Sources
5
Review
n/a
Overview
Tesamorelin is a synthetic analogue of human GHRH that stimulates pituitary release of endogenous growth hormone and increases IGF-1.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
FDA-labeled (Egrifta family) for reducing excess abdominal fat in HIV-infected adults with lipodystrophy; not labeled for general weight loss or anti-aging.
Interactions & cautions
Drug interactions
exogenous growth hormone or other GH secretagogues — Additive IGF-1 elevation and fluid-retention risk (review)
insulin or antidiabetic medications — Glycemic control may worsen or require regimen changes (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw